SCHEMBL5832789

SCHEMBL5832789

Cc1ccc(C(=O)Nc2ccccc2O)cc1Br

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.57
RAB9A P51151 3/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
MTOR P42345 3/20 0.55
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
TP53 P04637 2/20 0.55
HPGD P15428 2/20 0.55
ALDH1A1 P00352 1/20 0.55
TERT O14746 1/20 0.54
TOP1 P11387 1/20 0.54
HDAC1 Q13547 1/20 0.54
HDAC8 Q9BY41 1/20 0.54
HDAC6 Q9UBN7 1/20 0.54
POLB P06746 1/20 0.52
MAPT P10636 1/20 0.50
SNCA P37840 1/20 0.50
DHODH Q02127 1/20 0.49
KCNMA1 Q12791 1/20 0.49
LMNA P02545 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12151208 0.86 KMT2A (0.72) NPC1RAB9AMEN1KMT2ATP53
SCHEMBL11695694 0.82 HDAC1 (0.58) NPC1RAB9AMEN1KMT2ATP53
SCHEMBL11587889 0.81 TOP1 (0.62) NPC1RAB9AMEN1KMT2ATP53
SCHEMBL14043612 0.80 NPC1 (0.75) NPC1RAB9ASMN1; SMN2MTORMEN1
SCHEMBL5832473 0.80 PDE4D (0.58) NPC1RAB9AMEN1KMT2ATP53
SCHEMBL6029925 0.79 NPC1 (0.82) NPC1RAB9AMEN1KMT2ATP53
SCHEMBL11587346 0.78 TOP1 (0.62) NPC1RAB9AMEN1KMT2ATP53
SCHEMBL16404286 0.78 NPC1 (0.70) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL30608697 0.78 NPC1 (0.70) NPC1RAB9AMEN1KMT2ATP53
SCHEMBL651227 0.78 NPC1 (0.70) NPC1RAB9AMEN1KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7087601-B2 Metabotropic glutamate receptor-5 modulators MERCK & CO., INC. (US) 2006-08-08 US disclosed
EP-1453815-A4 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS MERCK & CO INC (US) 2005-04-06 EP disclosed
US-20050065340-A1 Metabotropic glutamate receptor-5 modulators MERCK SHARP & DOHME CORP. 2005-03-24 US disclosed
EP-1453815-A1 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS Merck & Co., Inc. (US) 2004-09-08 EP disclosed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO disclosed
WO-2003048137-A1 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS MERCK & CO., INC. (US) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065340-A1 Metabotropic glutamate receptor-5 modulators GRM5, GRIK5, GRM1 NPC1 3080/4885RAB9A 1104/4885SMN1; SMN2 3132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.